Direct Comparison of Four Hematopoietic Differentiation Methods from Human Induced Pluripotent Stem Cells

Induced pluripotent stem cells (iPSCs) are an invaluable resource for the study of human disease. However, there are no standardized methods for differentiation into hematopoietic cells, and there is a lack of robust, direct comparisons of different methodologies. In the current study we improved a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Stem cell reports 2020-09, Vol.15 (3), p.735-748
Hauptverfasser: Tursky, Melinda L., Loi, To Ha, Artuz, Crisbel M., Alateeq, Suad, Wolvetang, Ernst J., Tao, Helen, Ma, David D., Molloy, Timothy J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Induced pluripotent stem cells (iPSCs) are an invaluable resource for the study of human disease. However, there are no standardized methods for differentiation into hematopoietic cells, and there is a lack of robust, direct comparisons of different methodologies. In the current study we improved a feeder-free, serum-free method for generation of hematopoietic cells from iPSCs, and directly compared this with three other commonly used strategies with respect to efficiency, repeatability, hands-on time, and cost. We also investigated their capability and sensitivity to model genetic hematopoietic disorders in cells derived from Down syndrome and β-thalassemia patients. Of these methods, a multistep monolayer-based method incorporating aryl hydrocarbon receptor hyperactivation (“2D-multistep”) was the most efficient, generating significantly higher numbers of CD34+ progenitor cells and functional hematopoietic progenitors, while being the most time- and cost-effective and most accurately recapitulating phenotypes of Down syndrome and β-thalassemia. [Display omitted] •Direct comparison of 4 serum & feeder-free iPSC hematopoietic differentiation methods•Comparison: cost-benefit efficiency, sensitivity to model genetic blood diseases•Presents an improved iPSC hematopoietic differentiation: 7× efficiency at 50% cost•Improved method = most live cells, CD34+, CFU; lowest cost; greatest sensitivity Tursky and colleagues addressed a vital, unmet need to aid method selection for iPSC hematopoietic differentiation for research and potentially clinical use, comparing four representative serum- and feeder-layer-free methods. Assessments include production efficiency of CD34+ and functional hematopoietic progenitor cells, cost-benefit analysis, and ability to recapitulate aberrant hematopoiesis. An optimized method proved the most efficient, cost-effective, and sensitive.
ISSN:2213-6711
2213-6711
DOI:10.1016/j.stemcr.2020.07.009